Skip to main content
GutCited

Curcumin per Ulcerative Colitis (UC)

B

Multicenter RCT (CUBE trial) showed curcumin (2 g/day) plus mesalamine maintained remission better than mesalamine alone. Reduced relapse rate from 20% to 5% over 12 months.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dcurcumin\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Multicenter RCT (CUBE trial) showed curcumin (2 g/day) plus mesalamine maintained remission better than mesalamine alone. Reduced relapse rate from 20% to 5% over 12 months.

Key Study Findings

Systematic Review
The Complementary and Alternative Roles of Curcumin in Treatment of Ulcerative Colitis: An Umbrella Review.
Dose: None vs: placebo or standard therapy Outcome: ulcerative colitis outcomes (18 outcomes across 7 SR/MAs) Effetto: None None

Popolazione: patients with ulcerative colitis

Other
Reactive Oxygen Species-Responsive Polymer Drug Delivery System Targeted Oxidative Stressed Colon Cells to Ameliorate Colitis.
Dose: None vs: untreated colitis controls Outcome: mitigation of colitis symptoms (ROS scavenging, barrier restoration, … Effetto: None None

Popolazione: UC animal model and oxidatively stressed colon cells

Systematic Review
Curcumin and multiple health outcomes: critical umbrella review of intervention meta-analyses.
Dose: None vs: Various comparators Outcome: Multiple health outcomes Effetto: None None

Popolazione: Human subjects across 25 meta-analyses

Review
Natural products for the treatment of ulcerative colitis: focus on the JAK/STAT pathway.
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: None

In Vitro
Curcumin attenuates ulcerative colitis via regulation of Sphingosine kinases 1/NF-κB signaling pathway.
Dose: None vs: DSS-induced UC mice Outcome: UC inflammation via SphK1/NF-kB pathway Effetto: None None

Popolazione: DSS-induced UC murine model

Key Statistics

5

Studi

400

Partecipanti

Positive

B

Grado

Referenced Papers

Pharmaceuticals (Basel, Switzerland) 2023 18 citazioni
American family physician 2022 38 citazioni
Advances in experimental … 2021 87 citazioni
European journal of … 2021 40 citazioni
Nutrients 2019 71 citazioni
Journal of medicinal … 2019 17 citazioni
Immunopharmacology and immunotoxicology 2018 96 citazioni
Gastroenterology clinics of … 2018 67 citazioni
The Medical clinics … 2017 9 citazioni
Annals of gastroenterology 2015 135 citazioni
Alimentary pharmacology & … 2013 128 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
500-1,500 mg/day with piperine (black pepper extract) for absorption
ibssupport:
500-1,000 mg/day
ucmaintenance:
2,000 mg/day (1 g twice daily) as adjunct to mesalamine

Limite massimo: Well-tolerated up to 8 g/day in clinical trials (most studies use 1-2 g/day)

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Mixed --
None -- Positive --
None -- Mixed --
None -- Positive --
None -- Mixed --
None -- Positive --
Varying dosages -- Positive --
None -- Positive --

Momento migliore per l'assunzione: With meals containing fat and black pepper for enhanced absorption

Safety & Side Effects

Effetti collaterali segnalati

  • GI discomfort (nausea, diarrhea, abdominal pain) at high doses
  • Yellow staining of skin/teeth with topical/oral contact
  • Increased gallbladder contractions (avoid with gallstones or bile duct obstruction)
  • Iron chelation (may reduce iron absorption at very high doses)

Interazioni note

  • Anticoagulants (curcumin has antiplatelet properties; may increase bleeding risk)
  • Chemotherapy agents (curcumin may alter drug metabolism via CYP enzyme inhibition)
  • Sulfasalazine (additive anti-inflammatory effect — may be beneficial in IBD)
  • Iron supplements (curcumin may chelate iron; space dosing)
  • Piperine/black pepper (enhances curcumin bioavailability by 2,000% — commonly co-administered)

Livello di assunzione massimo tollerabile: Well-tolerated up to 8 g/day in clinical trials (most studies use 1-2 g/day)

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Curcumin help with Ulcerative Colitis (UC)?
Based on 5 studies with 400 participants, there is moderate evidence from clinical studies that Curcumin may support Ulcerative Colitis (UC) management. Our evidence grade is B (Good Evidence).
How much Curcumin should I take for Ulcerative Colitis (UC)?
Studies have used various dosages. A commonly studied range is 500-1,500 mg/day with piperine (black pepper extract) for absorption. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Curcumin?
Reported side effects may include GI discomfort (nausea, diarrhea, abdominal pain) at high doses, Yellow staining of skin/teeth with topical/oral contact, Increased gallbladder contractions (avoid with gallstones or bile duct obstruction), Iron chelation (may reduce iron absorption at very high doses). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Curcumin and Ulcerative Colitis (UC)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 5 peer-reviewed studies with 400 total participants. The overall direction of effect is positive.

Related Evidence

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.